The Endocrine Society has officially signaled its support for the newly introduced Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act, a significant piece of bipartisan legislation aimed at curbing the soaring costs of insulin for millions of Americans. Introduced in the House of Representatives by a cross-party coalition including Representatives Diana DeGette (D-CO), Mariannette Miller-Meeks (R-IA), Kim Schrier (D-WA), Rob Bresnahan (R-PA), and Angie Craig (D-MN), the bill represents a coordinated federal effort to bridge the gap in healthcare affordability. By targeting out-of-pocket costs and enhancing market competition, the legislation seeks to provide a permanent solution to a crisis that has forced many patients to choose between their medication and their basic survival needs.
The INSULIN Act arrives at a critical juncture in American healthcare, as the disparity between the cost of production and the retail price of insulin remains a point of intense public and political scrutiny. For the Endocrine Society, the world’s oldest and largest organization of scientists and physicians dedicated to hormone research and clinical care, the bill is a necessary evolution of current policy. It addresses not only the financial burden on those with private insurance but also the systemic hurdles faced by the uninsured, who are often the most vulnerable to the life-threatening consequences of insulin rationing.
Legislative Framework and Key Provisions
The INSULIN Act is designed with a multi-pronged approach to stabilize the insulin market and protect consumers. Its most prominent feature is the establishment of a $35 monthly cap on out-of-pocket costs for insulin products for individuals covered by private insurance. This provision mirrors similar protections already enacted for Medicare beneficiaries under the Inflation Reduction Act of 2022, effectively extending those safeguards to the broader commercial market.
Beyond the price cap, the legislation acknowledges that a significant portion of the population remains outside the traditional insurance safety net. To address this, the bill mandates the creation of a dedicated resource center and a national hotline. These tools are intended to assist uninsured patients in navigating the complex landscape of patient assistance programs, state-level subsidies, and charitable resources that can provide them with the lifesaving medication they require.
Furthermore, the INSULIN Act seeks to foster long-term price stability by promoting the development and market entry of biosimilar insulin products. By streamlining the path for competition, the bill aims to break the market dominance of a few major manufacturers, which has historically contributed to high list prices. This focus on biosimilars is intended to create a more robust and competitive marketplace, ultimately driving down costs for both insurers and patients through natural market dynamics.
The Scope of the Diabetes Crisis in the United States
The urgency of this legislation is underscored by the staggering prevalence of diabetes across the nation. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 38.4 million Americans—nearly 11.6% of the total population—are living with diabetes. Of these, all individuals with type 1 diabetes and many with type 2 diabetes require daily insulin injections to regulate their blood glucose levels.
For these patients, insulin is not an optional treatment but a biological necessity. Without it, they risk entering diabetic ketoacidosis (DKA), a medical emergency that can lead to coma or death. Despite its essential nature, the cost of insulin has historically outpaced inflation. Data from 2021 indicates that nearly one in five American adults with diabetes—roughly 1.3 million people—resorted to rationing their insulin due to cost concerns. Rationing involves taking less than the prescribed dose or skipping doses entirely, a practice that leads to devastating long-term complications, including kidney failure, blindness, limb amputations, and cardiovascular disease.
A Chronology of the Insulin Affordability Movement
The introduction of the INSULIN Act in the House of Representatives is the latest milestone in a decades-long struggle to manage the cost of a drug that was discovered over a century ago.
- 1921: Sir Frederick Banting and Charles Best discover insulin at the University of Toronto. To ensure the drug remained accessible, they sold the patent for a mere $1, famously stating, "Insulin does not belong to me, it belongs to the world."
- Late 20th Century: The transition from animal-derived insulin to synthetic, "human" insulin through recombinant DNA technology leads to the development of insulin analogs. While more effective, these new formulations were protected by new patents, leading to significant price increases.
- 2010s: The list prices of the most commonly used insulin products in the U.S. triple, sparking national outrage and congressional hearings.
- 2022: The Inflation Reduction Act is signed into law, capping insulin costs at $35 per month for seniors on Medicare. However, a similar cap for the private insurance market was removed from the bill due to Senate procedural rules.
- 2023: Under immense public and political pressure, the three major insulin manufacturers—Eli Lilly, Novo Nordisk, and Sanofi—announce voluntary price caps and reductions for many of their products.
- 2024: The INSULIN Act is introduced in the House, aiming to codify these protections into federal law and expand them to ensure permanent, universal access regardless of shifts in corporate policy.
Endorsements and Professional Perspectives
The Endocrine Society’s endorsement of the INSULIN Act is rooted in its long-standing advocacy for patient-centered care. Robert W. Lash, MD, the Society’s Chief Medical Officer, emphasized that the legislation aligns with the organization’s "Insulin Access and Affordability Position Statement." This policy document has long called for legislative intervention to limit co-pays to no more than $35 per month.
"For the millions of Americans who rely on insulin every day, no one should have to choose between paying for their medication and meeting other basic needs," stated Dr. Lash. "The Endocrine Society applauds Representatives DeGette, Schrier, Miller-Meeks, and Bresnahan for introducing the INSULIN Act. This bipartisan legislation is an important step toward ensuring that all people who need insulin can obtain it and stay healthy."
The Society’s support highlights a consensus among medical professionals that the current pricing model is unsustainable and medically dangerous. Physicians frequently report that they must spend significant clinical time helping patients find coupons or alternative brands rather than focusing on direct medical management, a phenomenon known as "administrative burden" that detracts from the quality of care.
Analysis of Economic and Public Health Implications
The potential impact of the INSULIN Act extends beyond the individual patient’s wallet. From a public health perspective, ensuring consistent access to insulin reduces the frequency of emergency room visits and hospitalizations. A single episode of diabetic ketoacidosis can cost the healthcare system tens of thousands of dollars—far more than the annual cost of providing affordable insulin.
Economically, the bill seeks to address the "middleman" problem in drug pricing. For years, Pharmacy Benefit Managers (PBMs) have been criticized for their role in the insulin supply chain. PBMs negotiate rebates with manufacturers, and critics argue that this system incentivizes high list prices. By capping out-of-pocket costs and encouraging biosimilar competition, the INSULIN Act puts pressure on the entire supply chain to prioritize affordability over rebate-driven profits.
The focus on biosimilars is particularly noteworthy. Unlike traditional generic drugs, which are exact chemical copies of brand-name medications, biosimilars are highly similar versions of complex biological products. Because they are more difficult to manufacture, the biosimilar market has been slow to develop. By including provisions to promote biosimilar competition, the INSULIN Act aims to replicate the cost-saving success seen in the generic drug market, which has saved the U.S. healthcare system trillions of dollars over the last few decades.
Addressing the Uninsured Gap
One of the most significant challenges in the insulin debate is the "coverage gap." While those with Medicare or robust private insurance may see relief, the uninsured often pay the full list price, which can exceed $300 per vial. The INSULIN Act’s proposed resource center and hotline are designed to serve as a navigator for this population.
While critics may argue that a resource center is not as effective as a direct subsidy, proponents suggest it is a pragmatic first step in a divided political climate. By connecting patients with existing manufacturer assistance programs (MAPs) and 340B drug pricing clinics, the government can facilitate immediate relief while continuing to debate broader healthcare reforms.
Future Outlook and Legislative Path
The INSULIN Act now moves to the committee stage in the House of Representatives, where it will undergo further refinement. Its bipartisan sponsorship is a positive indicator of its potential for success, as insulin affordability is an issue that resonates across the political spectrum and in every geographic region of the country.
Parallel efforts are also underway in the Senate, where Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME) have led similar bipartisan initiatives. The alignment between the House and Senate versions of the bill increases the likelihood of a unified piece of legislation reaching the President’s desk.
The Endocrine Society has pledged to continue its advocacy work, collaborating with lawmakers in both chambers to ensure the final version of the bill is as comprehensive as possible. As the legislative process unfolds, the focus remains on the millions of Americans who monitor their blood sugar daily, hoping for a future where their health is not dictated by the price of a century-old discovery.
In conclusion, the introduction of the INSULIN Act represents more than just a policy shift; it is a recognition of the fundamental right to accessible healthcare. By combining price caps, support for the uninsured, and market-based competition, the bill offers a holistic strategy to end the insulin affordability crisis in the United States. For the medical community and the patients they serve, the passage of this act would mark a historic victory for public health over economic barriers.
